{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"5.920","floor":"5.380"},"ipodate":{"start":"2014-06-26 00:00:00","end":"2014-07-02 00:00:00"},"minimumcapital":"2989.84","subscribed":"14.77","marketcap":"196.61億","H_marketcap":"--","pe":"7.34","codesrate":"60.20","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/02186/LTN20140626018_C.pdf","ipopricing":"5.920","resultdate":"2014-07-08 00:00:00","enddate":"2014-07-02 00:00:00","listeddate":"2014-07-09 00:00:00","issuenumber":"99964.00萬","issuenumberhK":"9996.40萬","issuenumberother":"89967.60萬","grayprice":"6.80","sponsors":"瑞銀證券香港有限公司,花旗環球金融亞洲有限公司,中信證券融資(香港)有限公司","raisemoney":"359200.00萬","use":"1、所得款項凈額約20%或約718百萬港元用于通過引入授權及其他安排（包括選擇性獲取經批準藥品的生產權或銷售及市場推廣權），旨在補充我們的現有藥品組合；\n2、所得款項凈額約20%或約718百萬港元用于研發（包括現有及未來中國及海外藥物開發項目）及涉及研發技術或進一步加強我們的研發能力及在研產品計劃的投資；\n3、所得款項凈額約20%或約718百萬港元用于選擇性收購國內外醫藥公司；\n4、所得款項凈額約20%或約718百萬港元用于撥充資本開支項目，通過構建新生產線以及升級及進一步推動現有生產設施自動化以增加我們的產能，以應對預期增加的我們目前產品及在研產品的需求；\n5、所得款項凈額約5%或約180百萬港元用于通過雇傭額外的市場推廣及銷售人員（包括專注于中樞神經系統產品的專責銷售人員）擴展我們的銷售及市場推廣網絡，設立額外的地區辦事處以增強我們現有產品的市場滲透，實現我們成功開發的在研產品的商業化及提高市場推廣及促銷活動（包括我們通過內部銷售團隊進行的學術推廣）的水平；\n6、所得款項凈額約5%或約180百萬港元將用于部份償還美元抵押貸款下的借款；\n7、所得款項凈額約10%或約360百萬港元將用作營運資金及一般公司用途。\n","shares":500,"leadagent":"瑞士銀行香港分行,花旗環球金融亞洲有限公司,中信里昂證券有限公司","bookrunners":"瑞士銀行香港分行,花旗環球金融亞洲有限公司,中信里昂證券有限公司","coordinator":"瑞士銀行香港分行,花旗環球金融亞洲有限公司,中信里昂證券有限公司","firstDayOpen":"6.80","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"花旗環球金融亞洲有限公司","code":"E02186","name":"綠葉制藥","fullname":"綠葉制藥集團有限公司"},"institutioninfo":{"principaloffice":"山東省煙臺市高新區創業路15號","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"劉殿波","secretary":"李美儀","telephone":"(86535) 6717618","substantialshareholders":"劉殿波及關連人士(46.32%)","principalactivities":"集團致力于在中國進行腫瘤科、心血管系統以及消化與代謝三個領域創新藥品的開發、生產、營銷及銷售。","website":"http://www.luye.cn"},"managerinfo":[],"investorinfo":[{"institutionname":"惠理基金管理香港有限公司","shareholding":"137,194,500.0","percentage":4.13,"ReleaseDate":"2015-01-09 00:00:00","relatedparty":"惠理集團有限公司","subsidiary":["惠理基金管理香港有限公司"],"InverstorType":"公司"},{"institutionname":"OrbiMed Funds","shareholding":"68,597,000.0","percentage":2.07,"ReleaseDate":"2015-01-09 00:00:00","relatedparty":"OrbiMed Capital LLC","subsidiary":["OrbiMed Funds","Worldwide Healthcare Trust PLC"],"InverstorType":"基金"},{"institutionname":"Dragon Billion China Master Fund","shareholding":"68,597,000.0","percentage":2.06,"ReleaseDate":"2015-01-09 00:00:00","relatedparty":"涌金資產管理有限公司","subsidiary":["Prime Capital Funds","Dragon Billion China Master Fund"],"InverstorType":"基金"},{"institutionname":"TAL China Focus Master Fund","shareholding":"41,158,500.0","percentage":1.24,"ReleaseDate":"2015-01-09 00:00:00","relatedparty":"Trivest Advisors Limited","subsidiary":["TAL China Focus Master Fund"],"InverstorType":"基金"}],"TotalShareholdingPercentage":11.56},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":507}